Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers

Natural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various solid tumors, and their numbers are correlated with good outcome. The function of NK cells extends their lytic capacities toward tumor cells ex...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 8; p. 683
Main Authors Messaoudene, Meriem, Frazao, Alexandra, Gavlovsky, Pierre Jean, Toubert, Antoine, Dulphy, Nicolas, Caignard, Anne
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 12.06.2017
Subjects
AMLMDS
BRAF inhibitor
immune checkpoint inhibitors
Immunology
melanoma
natural killer ligands
tumour immunosurveillance
BRAF inhibitor
melanoma
tumour immunosurveillance
immune checkpoint inhibitors
AMLMDS
natural killer ligands
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2017.00683

Cover

Abstract Natural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various solid tumors, and their numbers are correlated with good outcome. The function of NK cells extends their lytic capacities toward tumor cells expressing stress-induced ligands, through secretion of immunoregulatory cytokines, and interactions with other immune cells. Altered NK cell function due to tumor immune escape is frequent in advanced tumors; however, strategies to release the function of NK infiltrating tumors are emerging. Recent therapies targeting specific oncogenic mutations improved the treatment of cancer patients, but patients often relapse. The actual development consists in combined therapeutic strategies including agents targeting the proliferation of tumor cells and others restorating functional antitumor immune effectors for efficient and durable efficacy of anticancer treatment. In that context, we discuss the recent results of the literature to propose hypotheses concerning the potential use of NK cells, potent antitumor cytotoxic effectors, to design novel antitumor strategies.
AbstractList Natural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various solid tumors, and their numbers are correlated with good outcome. The function of NK cells extends their lytic capacities toward tumor cells expressing stress-induced ligands, through secretion of immunoregulatory cytokines, and interactions with other immune cells. Altered NK cell function due to tumor immune escape is frequent in advanced tumors; however, strategies to release the function of NK infiltrating tumors are emerging. Recent therapies targeting specific oncogenic mutations improved the treatment of cancer patients, but patients often relapse. The actual development consists in combined therapeutic strategies including agents targeting the proliferation of tumor cells and others restorating functional antitumor immune effectors for efficient and durable efficacy of anticancer treatment. In that context, we discuss the recent results of the literature to propose hypotheses concerning the potential use of NK cells, potent antitumor cytotoxic effectors, to design novel antitumor strategies.Natural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various solid tumors, and their numbers are correlated with good outcome. The function of NK cells extends their lytic capacities toward tumor cells expressing stress-induced ligands, through secretion of immunoregulatory cytokines, and interactions with other immune cells. Altered NK cell function due to tumor immune escape is frequent in advanced tumors; however, strategies to release the function of NK infiltrating tumors are emerging. Recent therapies targeting specific oncogenic mutations improved the treatment of cancer patients, but patients often relapse. The actual development consists in combined therapeutic strategies including agents targeting the proliferation of tumor cells and others restorating functional antitumor immune effectors for efficient and durable efficacy of anticancer treatment. In that context, we discuss the recent results of the literature to propose hypotheses concerning the potential use of NK cells, potent antitumor cytotoxic effectors, to design novel antitumor strategies.
Natural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various solid tumors, and their numbers are correlated with good outcome. The function of NK cells extends their lytic capacities toward tumor cells expressing stress-induced ligands, through secretion of immunoregulatory cytokines, and interactions with other immune cells. Altered NK cell function due to tumor immune escape is frequent in advanced tumors; however, strategies to release the function of NK infiltrating tumors are emerging. Recent therapies targeting specific oncogenic mutations improved the treatment of cancer patients, but patients often relapse. The actual development consists in combined therapeutic strategies including agents targeting the proliferation of tumor cells and others restorating functional antitumor immune effectors for efficient and durable efficacy of anticancer treatment. In that context, we discuss the recent results of the literature to propose hypotheses concerning the potential use of NK cells, potent antitumor cytotoxic effectors, to design novel antitumor strategies.
Author Gavlovsky, Pierre Jean
Toubert, Antoine
Caignard, Anne
Frazao, Alexandra
Dulphy, Nicolas
Messaoudene, Meriem
AuthorAffiliation 1 INSERM U1015, Gustave Roussy Cancer Campus , Villejuif , France
3 INSERM U1160, Institut Universitaire d’Hématologie, Hôpital Saint Louis , Paris , France
2 Gustave Roussy Cancer Campus , Villejuif , France
AuthorAffiliation_xml – name: 2 Gustave Roussy Cancer Campus , Villejuif , France
– name: 1 INSERM U1015, Gustave Roussy Cancer Campus , Villejuif , France
– name: 3 INSERM U1160, Institut Universitaire d’Hématologie, Hôpital Saint Louis , Paris , France
Author_xml – sequence: 1
  givenname: Meriem
  surname: Messaoudene
  fullname: Messaoudene, Meriem
– sequence: 2
  givenname: Alexandra
  surname: Frazao
  fullname: Frazao, Alexandra
– sequence: 3
  givenname: Pierre Jean
  surname: Gavlovsky
  fullname: Gavlovsky, Pierre Jean
– sequence: 4
  givenname: Antoine
  surname: Toubert
  fullname: Toubert, Antoine
– sequence: 5
  givenname: Nicolas
  surname: Dulphy
  fullname: Dulphy, Nicolas
– sequence: 6
  givenname: Anne
  surname: Caignard
  fullname: Caignard, Anne
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28659921$$D View this record in MEDLINE/PubMed
BookMark eNp1kstuEzEUhi3UipbSPSvkJZsE38YXFkgoKqWiahEKC1aWZ2wnrjzjYM8gseM1-no8CU7SorYSXtiWz_m_Y53zvwAHQxocAK8wmlMq1Vsf-n6aE4TFHCEu6TNwjDlnM0oIO3hwPwKnpdygupiilDbPwRGRvFGK4GPw_YsZgxvGP79vC7wy45RNhJ9DjC7DhYuxwDDAce3gWTYwebg0eeVGZ-Fy7bLZBFfewa8pOuhThsupr_teXV6CQ29icad35wn49vFsufg0u7w-v1h8uJx1jJNxZqVlyDJhsWvrr1grTNtwJjySkjSUt7xVvsPCE8KRF9YQi5pOcsExaQXl9ARc7Lk2mRu9yaE3-ZdOJujdQ8orbfIYuui0QVh1UglJMGauaVsmESVSeYqIqcHKer9nbaa2d7arjan9eAR9HBnCWq_ST90wzhVvKuDNHSCnH5Mro-5D6WofzeDSVDRWmMkGISxr6uuHtf4VuZ9NTeD7hC6nUrLzugtjnVbalg5RY6S3PtA7H-itD_TOB1WIngjv2f-V_AUj57Xa
CitedBy_id crossref_primary_10_1016_j_ejcb_2018_12_003
crossref_primary_10_1080_10428194_2020_1849680
crossref_primary_10_1136_jitc_2022_005632
crossref_primary_10_1042_CS20191170
crossref_primary_10_3390_cancers13205042
crossref_primary_10_1097_PPO_0000000000000517
crossref_primary_10_1186_s13045_020_00998_9
crossref_primary_10_1007_s12032_023_02019_4
crossref_primary_10_3390_ijms20030756
Cites_doi 10.1007/s10585-006-9043-9
10.1080/2162402X.2015.1137418
10.1371/journal.pone.0076928
10.1126/science.1068440
10.1182/blood-2013-08-519199
10.1146/annurev.immunol.19.1.197
10.1073/pnas.0901653106
10.1182/blood-2010-08-301945
10.1182/blood-2005-08-027979
10.1093/annonc/mdt587
10.1158/0008-5472.CAN-14-1339
10.1177/1758834015616934
10.1038/cmi.2013.9
10.1182/blood.V88.6.2279.bloodjournal8862279
10.1172/JCI66236
10.1172/JCI45816
10.1038/nri1199
10.1182/blood-2009-02-206532
10.1182/blood-2012-06-438028
10.1002/eji.201444500
10.3389/fimmu.2014.00122
10.1016/j.immuni.2008.02.016
10.1097/CJI.0b013e3181ab23f1
10.1038/sj.emboj.7600019
10.1016/j.jss.2010.05.012
10.1158/0008-5472.CAN-13-1303
10.4049/jimmunol.1301889
10.1038/ncomms12258
10.1038/leu.2012.87
10.1016/j.humpath.2011.02.019
10.1038/nri3365
10.1186/1756-8722-7-33
10.1097/CMR.0b013e32833e3286
10.4161/onci.20226
10.1002/ijc.2910160204
10.1016/j.bbmt.2010.03.004
10.4049/jimmunol.180.9.6392
10.1016/S0140-6736(00)03231-1
10.1084/jem.191.8.1259
10.1080/2162402X.2016.1163456
10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V
10.1038/35869
10.1189/jlb.0710422
10.1038/sj.leu.2404892
10.1158/1078-0432.CCR-12-3847
10.1155/2011/379123
10.4161/onci.19864
10.1158/0008-5472.CAN-05-2776
10.1038/icb.2011.15
10.4049/jimmunol.0901644
10.1182/blood-2004-04-1441
10.1182/blood.V99.10.3661
10.1146/annurev.immunol.22.012703.104803
10.1016/j.febslet.2013.11.030
10.18632/oncotarget.11504
10.1158/0008-5472.CAN-10-4179
10.1016/S0169-5002(01)00292-6
10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P
10.1080/2162402X.2016.1154251
10.3389/fimmu.2016.00413
10.1016/j.immuni.2016.01.024
10.1080/21645515.2015.1096458
10.1182/blood-2010-05-283051
10.1158/0008-5472.CAN-13-0371
10.1158/0008-5472.CAN-10-0118
10.1182/blood-2012-06-437558
10.1038/nm.2366
10.1186/1471-2407-9-186
10.1084/jem.169.6.2233
10.1200/JCO.2005.03.9594
10.4049/jimmunol.172.4.2048
10.1158/1078-0432.CCR-10-1911
10.1182/blood-2008-10-182048
10.1146/annurev-immunol-031210-101324
10.1158/0008-5472.CAN-06-4406
10.1182/blood-2011-06-360255
10.3324/haematol.2013.087536
10.1016/j.jim.2009.06.004
10.1182/blood-2007-09-077438
10.1172/JCI0215950
10.1067/mtc.2001.113026
10.3389/fimmu.2015.00202
10.1002/eji.1830050209
10.4049/jimmunol.1500262
10.1158/1078-0432.CCR-10-2173
ContentType Journal Article
Copyright Copyright © 2017 Messaoudene, Frazao, Gavlovsky, Toubert, Dulphy and Caignard. 2017 Messaoudene, Frazao, Gavlovsky, Toubert, Dulphy and Caignard
Copyright_xml – notice: Copyright © 2017 Messaoudene, Frazao, Gavlovsky, Toubert, Dulphy and Caignard. 2017 Messaoudene, Frazao, Gavlovsky, Toubert, Dulphy and Caignard
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2017.00683
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_a019c89782114e5bb4803289f302aa01
PMC5466965
28659921
10_3389_fimmu_2017_00683
Genre Journal Article
GrantInformation_xml – fundername: Institut National Du Cancer
  grantid: PAIR-melanome 2013-1 MELA 03-1
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c462t-d8d40d47d1eb8654b7ab5647f0882536b6b9fc17f2260f7da2d05c867612b7363
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:20:01 EDT 2025
Thu Aug 21 18:17:18 EDT 2025
Fri Sep 05 08:24:26 EDT 2025
Thu Jan 02 22:22:03 EST 2025
Tue Jul 01 01:57:39 EDT 2025
Thu Apr 24 22:56:41 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords BRAF inhibitor
melanoma
tumour immunosurveillance
immune checkpoint inhibitors
AMLMDS
natural killer ligands
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-d8d40d47d1eb8654b7ab5647f0882536b6b9fc17f2260f7da2d05c867612b7363
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Specialty section: This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology
Edited by: Ulrike Koehl, Hannover Medical School, Germany
Reviewed by: Christian Kalberer, University of Basel, Switzerland; Ralf Dressel, Universitätsmedizin Göttingen, Germany
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2017.00683
PMID 28659921
PQID 1914850018
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_a019c89782114e5bb4803289f302aa01
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5466965
proquest_miscellaneous_1914850018
pubmed_primary_28659921
crossref_citationtrail_10_3389_fimmu_2017_00683
crossref_primary_10_3389_fimmu_2017_00683
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-06-12
PublicationDateYYYYMMDD 2017-06-12
PublicationDate_xml – month: 06
  year: 2017
  text: 2017-06-12
  day: 12
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2017
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Donskov (B41) 2006; 24
Chretien (B61) 2014; 5
Moretta (B8) 2004; 23
Ferrari de Andrade (B62) 2014; 74
Bottos (B67) 2016; 7
Stringaris (B27) 2014; 99
Konjevic (B54) 2010; 20
Sanchez-Correa (B24) 2012; 90
Comin-Anduix (B58) 2010; 16
Wittnebel (B34) 2007; 67
Kohrt (B71) 2014; 123
Costello (B22) 2002; 99
Knight (B63) 2013; 123
Hooijkaas (B65) 2012; 1
Messaoudene (B15) 2016; 5
Braud (B11) 1998; 391
Binyamin (B86) 2008; 180
Kiessling (B2) 1975; 5
Moretta (B9) 2001; 19
Breton (B77) 2014; 7
Mirjacic Martinovic (B52) 2011; 171
Fregni (B55) 2013; 8
Cooley (B31) 2010; 116
McKay (B48) 2011; 42
Khaznadar (B28) 2015; 195
Pierson (B21) 1996; 88
Delahaye (B47) 2011; 17
Hayashi (B13) 2006; 66
Stringaris (B32) 2010; 16
Halama (B39) 2011; 17
Lanier (B7) 2000; 191
Kornstein (B35) 1987; 47
Mamessier (B49) 2011; 121
Messaoudene (B50) 2014; 74
Alderson (B76) 2011; 2011
Navarro (B75) 2015; 29
Brady (B82) 2004; 172
Betting (B83) 2009; 32
Fauriat (B23) 2007; 109
Vesely (B18) 2011; 29
Khaznadar (B26) 2014; 44
Coca (B46) 1997; 79
Kohrt (B85) 2011; 117
Carrega (B37) 2014; 192
Romagne (B68) 2009; 114
Ruggeri (B29) 2002; 295
Zalevsky (B80) 2009; 113
Lanier (B5) 1989; 169
Guerra (B20) 2008; 28
Fend (B14) 2017; 6
Imai (B12) 2000; 356
Konjevic (B53) 2007; 24
Sun (B3) 2013; 10
Cheung (B79) 2012; 1
Takanami (B40) 2001; 121
Gannon (B43) 2009; 348
Ishigami (B45) 2000; 88
Lion (B25) 2012; 26
Rusakiewicz (B16) 2017; 6
Dunn (B17) 2004; 22
Remark (B42) 2013; 19
Vey (B72) 2012; 120
Garcia-Iglesias (B56) 2009; 9
Benson (B69) 2011; 118
Raulet (B10) 2003; 3
Eroglu (B57) 2016; 8
Caligiuri (B6) 2008; 112
Parihar (B81) 2002; 110
Schilling (B59) 2014; 25
Villegas (B44) 2002; 35
Ebert (B66) 2016; 44
Herberman (B1) 1975; 16
Spits (B4) 2013; 13
Rusakiewicz (B38) 2013; 73
Buhtoiarov (B84) 2011; 89
Murray (B74) 2016; 12
Beelen (B30) 2005; 105
Elboim (B19) 2010; 184
Rocca (B51) 2016; 7
Manzini (B60) 2016; 7
Savani (B33) 2007; 21
Benson (B73) 2012; 120
Platonova (B36) 2011; 71
Ahmed (B78) 2014; 588
Sola (B70) 2009; 106
Boni (B64) 2010; 70
25972872 - Front Immunol. 2015 Apr 29;6:202
23033266 - Blood. 2012 Nov 22;120(22):4324-33
15032581 - Annu Rev Immunol. 2004;22:329-60
23563087 - Cell Mol Immunol. 2013 May;10(3):202-12
15536148 - Blood. 2005 Mar 15;105(6):2594-600
20581313 - Blood. 2010 Oct 7;116(14):2411-9
21841316 - J Clin Invest. 2011 Sep;121(9):3609-22
11117911 - Lancet. 2000 Nov 25;356(9244):1795-9
20828749 - J Surg Res. 2011 Dec;171(2):637-49
21325295 - Clin Cancer Res. 2011 Feb 15;17(4):678-89
23348417 - Nat Rev Immunol. 2013 Feb;13(2):145-9
18424763 - J Immunol. 2008 May 1;180(9):6392-401
18650461 - Blood. 2008 Aug 1;112(3):461-9
16648500 - J Clin Oncol. 2006 May 1;24(13):1997-2005
24295643 - FEBS Lett. 2014 Jan 21;588(2):288-97
20302958 - Biol Blood Marrow Transplant. 2010 Sep;16(9):1257-64
21219185 - Annu Rev Immunol. 2011;29:235-71
11986221 - Blood. 2002 May 15;99(10):3661-7
14685277 - EMBO J. 2004 Jan 28;23(2):255-9
28123867 - Oncoimmunology. 2016 Mar 10;5(12 ):e1154251
26246143 - J Immunol. 2015 Sep 15;195(6):2580-90
9191519 - Cancer. 1997 Jun 15;79(12):2320-8
14764669 - J Immunol. 2004 Feb 15;172(4):2048-58
21708957 - Cancer Res. 2011 Aug 15;71(16):5412-22
19531227 - BMC Cancer. 2009 Jun 16;9:186
11750709 - Lung Cancer. 2002 Jan;35(1):23-8
23785047 - Clin Cancer Res. 2013 Aug 1;19(15):4079-91
26944201 - Immunity. 2016 Mar 15;44(3):609-21
23592754 - Cancer Res. 2013 Jun 15;73(12):3499-510
28197361 - Oncoimmunology. 2016 Apr 25;6(1):e1137418
3815344 - Cancer Res. 1987 Mar 1;47(5):1411-2
19552894 - J Immunol Methods. 2009 Aug 31;348(1-2):9-17
24646734 - J Immunol. 2014 Apr 15;192(8):3805-15
19561305 - Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84
22031859 - Blood. 2011 Dec 8;118(24):6387-91
11244035 - Annu Rev Immunol. 2001;19:197-223
21660134 - J Biomed Biotechnol. 2011;2011:379123
26402368 - Hum Vaccin Immunother. 2016 Mar 3;12(3):607-11
19553639 - Blood. 2009 Sep 24;114(13):2667-77
18394936 - Immunity. 2008 Apr;28(4):571-80
24731302 - J Hematol Oncol. 2014 Apr 14;7:33
24715892 - Front Immunol. 2014 Mar 24;5:122
24326534 - Blood. 2014 Jan 30;123(5):678-86
22754766 - Oncoimmunology. 2012 Jul 1;1(4):477-486
8822949 - Blood. 1996 Sep 15;88(6):2279-87
17295095 - Clin Exp Metastasis. 2007;24(1):1-11
11896281 - Science. 2002 Mar 15;295(5562):2097-100
25041786 - Eur J Immunol. 2014 Oct;44(10):3068-80
1080480 - Int J Cancer. 1975 Aug 15;16(2):230-9
9486650 - Nature. 1998 Feb 19;391(6669):795-9
26753005 - Ther Adv Med Oncol. 2016 Jan;8(1):48-56
19483647 - J Immunother. 2009 Jul-Aug;32(6):622-31
21676435 - Hum Pathol. 2011 Dec;42(12):1960-4
23454771 - J Clin Invest. 2013 Mar;123(3):1371-81
11385371 - J Thorac Cardiovasc Surg. 2001 Jun;121(6):1058-63
24488563 - Haematologica. 2014 May;99(5):836-47
10649250 - Cancer. 2000 Feb 1;88(3):577-83
17575122 - Cancer Res. 2007 Jun 15;67(12):5594-9
22934253 - Oncoimmunology. 2012 Aug 1;1(5):609-617
16397273 - Cancer Res. 2006 Jan 1;66(1):563-70
23002117 - Blood. 2012 Nov 22;120(22):4317-23
21169256 - Clin Cancer Res. 2010 Dec 15;16(24):6040-8
22446501 - Leukemia. 2012 Sep;26(9):2019-26
21248148 - J Leukoc Biol. 2011 Apr;89(4):625-38
20551059 - Cancer Res. 2010 Jul 1;70(13):5213-9
20404273 - J Immunol. 2010 May 15;184(10):5637-44
21552268 - Nat Med. 2011 Jun;17(6):700-7
24225017 - Cancer Res. 2014 Jan 1;74(1):81-92
21193697 - Blood. 2011 Feb 24;117(8):2423-32
28197362 - Oncoimmunology. 2016 May 13;6(1):e1163456
27563819 - Oncotarget. 2016 Sep 20;7(38):60858-60871
17673900 - Leukemia. 2007 Oct;21(10):2145-52
12370276 - J Clin Invest. 2002 Oct;110(7):983-92
25351955 - Cancer Res. 2014 Dec 15;74(24):7298-308
20938360 - Melanoma Res. 2010 Dec;20(6):459-67
16940427 - Blood. 2007 Jan 1;109(1):323-30
27777574 - Front Immunol. 2016 Oct 10;7:413
2471777 - J Exp Med. 1989 Jun 1;169(6):2233-8
1234049 - Eur J Immunol. 1975 Feb;5(2):112-7
24504444 - Ann Oncol. 2014 Mar;25(3):747-53
14523385 - Nat Rev Immunol. 2003 Oct;3(10):781-90
10770793 - J Exp Med. 2000 Apr 17;191(8):1259-62
19109559 - Blood. 2009 Apr 16;113(16):3735-43
21383766 - Immunol Cell Biol. 2012 Jan;90(1):109-15
24204708 - PLoS One. 2013 Oct 18;8(10):e76928
27406745 - Nat Commun. 2016 Jul 13;7:12258
References_xml – volume: 24
  start-page: 1
  year: 2007
  ident: B53
  article-title: Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients
  publication-title: Clin Exp Metastasis
  doi: 10.1007/s10585-006-9043-9
– volume: 6
  start-page: e1137418
  year: 2017
  ident: B16
  article-title: NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2015.1137418
– volume: 47
  start-page: 1411
  year: 1987
  ident: B35
  article-title: Natural killer cells in the host response to melanoma
  publication-title: Cancer Res
– volume: 8
  start-page: e76928
  year: 2013
  ident: B55
  article-title: Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0076928
– volume: 295
  start-page: 2375
  year: 2002
  ident: B29
  article-title: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
  publication-title: Science
  doi: 10.1126/science.1068440
– volume: 123
  start-page: 678
  year: 2014
  ident: B71
  article-title: Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
  publication-title: Blood
  doi: 10.1182/blood-2013-08-519199
– volume: 19
  start-page: 197
  year: 2001
  ident: B9
  article-title: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.19.1.197
– volume: 106
  start-page: 12879
  year: 2009
  ident: B70
  article-title: Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0901653106
– volume: 117
  start-page: 2423
  year: 2011
  ident: B85
  article-title: CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
  publication-title: Blood
  doi: 10.1182/blood-2010-08-301945
– volume: 109
  start-page: 323
  year: 2007
  ident: B23
  article-title: Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
  publication-title: Blood
  doi: 10.1182/blood-2005-08-027979
– volume: 25
  start-page: 747
  year: 2014
  ident: B59
  article-title: Differential influence of vemurafenib and dabrafenib on patients’ lymphocytes despite similar clinical efficacy in melanoma
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt587
– volume: 74
  start-page: 7298
  year: 2014
  ident: B62
  article-title: Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-1339
– volume: 8
  start-page: 48
  year: 2016
  ident: B57
  article-title: Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
  publication-title: Ther Adv Med Oncol
  doi: 10.1177/1758834015616934
– volume: 10
  start-page: 202
  year: 2013
  ident: B3
  article-title: NK cells in immunotolerant organs
  publication-title: Cell Mol Immunol
  doi: 10.1038/cmi.2013.9
– volume: 88
  start-page: 2279
  year: 1996
  ident: B21
  article-title: CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis
  publication-title: Blood
  doi: 10.1182/blood.V88.6.2279.bloodjournal8862279
– volume: 123
  start-page: 1371
  year: 2013
  ident: B63
  article-title: Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
  publication-title: J Clin Invest
  doi: 10.1172/JCI66236
– volume: 121
  start-page: 3609
  year: 2011
  ident: B49
  article-title: Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
  publication-title: J Clin Invest
  doi: 10.1172/JCI45816
– volume: 3
  start-page: 781
  year: 2003
  ident: B10
  article-title: Roles of the NKG2D immunoreceptor and its ligands
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri1199
– volume: 114
  start-page: 2667
  year: 2009
  ident: B68
  article-title: Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
  publication-title: Blood
  doi: 10.1182/blood-2009-02-206532
– volume: 120
  start-page: 4324
  year: 2012
  ident: B73
  article-title: A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2012-06-438028
– volume: 44
  start-page: 3068
  year: 2014
  ident: B26
  article-title: Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201444500
– volume: 5
  start-page: 122
  year: 2014
  ident: B61
  article-title: Cancer-induced alterations of NK-mediated target recognition: current and investigational pharmacological strategies aiming at restoring NK-mediated anti-tumor activity
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2014.00122
– volume: 28
  start-page: 571
  year: 2008
  ident: B20
  article-title: NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
  publication-title: Immunity
  doi: 10.1016/j.immuni.2008.02.016
– volume: 32
  start-page: 622
  year: 2009
  ident: B83
  article-title: Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma
  publication-title: J Immunother
  doi: 10.1097/CJI.0b013e3181ab23f1
– volume: 23
  start-page: 255
  year: 2004
  ident: B8
  article-title: Unravelling natural killer cell function: triggering and inhibitory human NK receptors
  publication-title: EMBO J
  doi: 10.1038/sj.emboj.7600019
– volume: 171
  start-page: 637
  year: 2011
  ident: B52
  article-title: The stage dependent changes in NK cell activity and the expression of activating and inhibitory NK cell receptors in melanoma patients
  publication-title: J Surg Res
  doi: 10.1016/j.jss.2010.05.012
– volume: 74
  start-page: 81
  year: 2014
  ident: B50
  article-title: Mature cytotoxic CD56bright/CD16+ natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-1303
– volume: 192
  start-page: 3805
  year: 2014
  ident: B37
  article-title: CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1301889
– volume: 7
  start-page: 12258
  year: 2016
  ident: B67
  article-title: Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models
  publication-title: Nat Commun
  doi: 10.1038/ncomms12258
– volume: 26
  start-page: 2019
  year: 2012
  ident: B25
  article-title: Natural killer cell immune escape in acute myeloid leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2012.87
– volume: 42
  start-page: 1960
  year: 2011
  ident: B48
  article-title: Association between natural killer cells and regression in melanocytic lesions
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2011.02.019
– volume: 13
  start-page: 145
  year: 2013
  ident: B4
  article-title: Innate lymphoid cells – a proposal for uniform nomenclature
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri3365
– volume: 7
  start-page: 33
  year: 2014
  ident: B77
  article-title: A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-7-33
– volume: 20
  start-page: 459
  year: 2010
  ident: B54
  article-title: In-vitro IL-2 or IFN-alpha-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients
  publication-title: Melanoma Res
  doi: 10.1097/CMR.0b013e32833e3286
– volume: 1
  start-page: 609
  year: 2012
  ident: B65
  article-title: Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma
  publication-title: Oncoimmunology
  doi: 10.4161/onci.20226
– volume: 16
  start-page: 230
  year: 1975
  ident: B1
  article-title: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910160204
– volume: 16
  start-page: 1257
  year: 2010
  ident: B32
  article-title: Donor KIR genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2010.03.004
– volume: 180
  start-page: 6392
  year: 2008
  ident: B86
  article-title: Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy
  publication-title: J Immunol
  doi: 10.4049/jimmunol.180.9.6392
– volume: 356
  start-page: 1795
  year: 2000
  ident: B12
  article-title: Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
  publication-title: Lancet
  doi: 10.1016/S0140-6736(00)03231-1
– volume: 191
  start-page: 1259
  year: 2000
  ident: B7
  article-title: Turning on natural killer cells
  publication-title: J Exp Med
  doi: 10.1084/jem.191.8.1259
– volume: 6
  start-page: e1163456
  year: 2017
  ident: B14
  article-title: Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1163456
– volume: 88
  start-page: 577
  year: 2000
  ident: B45
  article-title: Prognostic value of intratumoral natural killer cells in gastric carcinoma
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V
– volume: 391
  start-page: 795
  year: 1998
  ident: B11
  article-title: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
  publication-title: Nature
  doi: 10.1038/35869
– volume: 89
  start-page: 625
  year: 2011
  ident: B84
  article-title: Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.0710422
– volume: 21
  start-page: 2145
  year: 2007
  ident: B33
  article-title: Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404892
– volume: 19
  start-page: 4079
  year: 2013
  ident: B42
  article-title: Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-3847
– volume: 2011
  start-page: 379123
  year: 2011
  ident: B76
  article-title: Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity
  publication-title: J Biomed Biotechnol
  doi: 10.1155/2011/379123
– volume: 1
  start-page: 477
  year: 2012
  ident: B79
  article-title: Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo
  publication-title: Oncoimmunology
  doi: 10.4161/onci.19864
– volume: 66
  start-page: 563
  year: 2006
  ident: B13
  article-title: Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2776
– volume: 90
  start-page: 109
  year: 2012
  ident: B24
  article-title: Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients
  publication-title: Immunol Cell Biol
  doi: 10.1038/icb.2011.15
– volume: 184
  start-page: 5637
  year: 2010
  ident: B19
  article-title: Tumor immunoediting by NKp46
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0901644
– volume: 105
  start-page: 2594
  year: 2005
  ident: B30
  article-title: Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias
  publication-title: Blood
  doi: 10.1182/blood-2004-04-1441
– volume: 99
  start-page: 3661
  year: 2002
  ident: B22
  article-title: Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood.V99.10.3661
– volume: 22
  start-page: 329
  year: 2004
  ident: B17
  article-title: The three Es of cancer immunoediting
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.22.012703.104803
– volume: 588
  start-page: 288
  year: 2014
  ident: B78
  article-title: Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy
  publication-title: FEBS Lett
  doi: 10.1016/j.febslet.2013.11.030
– volume: 7
  start-page: 60858
  year: 2016
  ident: B60
  article-title: Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11504
– volume: 71
  start-page: 5412
  year: 2011
  ident: B36
  article-title: Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-4179
– volume: 35
  start-page: 23
  year: 2002
  ident: B44
  article-title: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/S0169-5002(01)00292-6
– volume: 79
  start-page: 2320
  year: 1997
  ident: B46
  article-title: The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P
– volume: 5
  start-page: e1154251
  year: 2016
  ident: B15
  article-title: NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: unique NKp30 pattern in rare melanoma patients with favorable evolution
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1154251
– volume: 7
  start-page: 413
  year: 2016
  ident: B51
  article-title: Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00413
– volume: 44
  start-page: 609
  year: 2016
  ident: B66
  article-title: Promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.01.024
– volume: 12
  start-page: 607
  year: 2016
  ident: B74
  article-title: Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: on being in the right place at the right time, with resilience
  publication-title: Hum Vaccin Immunother
  doi: 10.1080/21645515.2015.1096458
– volume: 116
  start-page: 2411
  year: 2010
  ident: B31
  article-title: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
  publication-title: Blood
  doi: 10.1182/blood-2010-05-283051
– volume: 73
  start-page: 3499
  year: 2013
  ident: B38
  article-title: Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-0371
– volume: 70
  start-page: 5213
  year: 2010
  ident: B64
  article-title: Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-0118
– volume: 120
  start-page: 4317
  year: 2012
  ident: B72
  article-title: A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
  publication-title: Blood
  doi: 10.1182/blood-2012-06-437558
– volume: 17
  start-page: 700
  year: 2011
  ident: B47
  article-title: Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
  publication-title: Nat Med
  doi: 10.1038/nm.2366
– volume: 9
  start-page: 186
  year: 2009
  ident: B56
  article-title: Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-9-186
– volume: 169
  start-page: 2233
  year: 1989
  ident: B5
  article-title: Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule
  publication-title: J Exp Med
  doi: 10.1084/jem.169.6.2233
– volume: 24
  start-page: 1997
  year: 2006
  ident: B41
  article-title: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.03.9594
– volume: 172
  start-page: 2048
  year: 2004
  ident: B82
  article-title: IL-21 induces the functional maturation of murine NK cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.4.2048
– volume: 16
  start-page: 6040
  year: 2010
  ident: B58
  article-title: The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-1911
– volume: 113
  start-page: 3735
  year: 2009
  ident: B80
  article-title: The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates
  publication-title: Blood
  doi: 10.1182/blood-2008-10-182048
– volume: 29
  start-page: 235
  year: 2011
  ident: B18
  article-title: Natural innate and adaptive immunity to cancer
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev-immunol-031210-101324
– volume: 67
  start-page: 5594
  year: 2007
  ident: B34
  article-title: Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-4406
– volume: 118
  start-page: 6387
  year: 2011
  ident: B69
  article-title: IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
  publication-title: Blood
  doi: 10.1182/blood-2011-06-360255
– volume: 99
  start-page: 836
  year: 2014
  ident: B27
  article-title: Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.087536
– volume: 348
  start-page: 9
  year: 2009
  ident: B43
  article-title: Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
  publication-title: J Immunol Methods
  doi: 10.1016/j.jim.2009.06.004
– volume: 112
  start-page: 461
  year: 2008
  ident: B6
  article-title: Human natural killer cells
  publication-title: Blood
  doi: 10.1182/blood-2007-09-077438
– volume: 110
  start-page: 983
  year: 2002
  ident: B81
  article-title: IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
  publication-title: J Clin Invest
  doi: 10.1172/JCI0215950
– volume: 121
  start-page: 1058
  year: 2001
  ident: B40
  article-title: The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma
  publication-title: J Thorac Cardiovasc Surg
  doi: 10.1067/mtc.2001.113026
– volume: 29
  start-page: 202
  year: 2015
  ident: B75
  article-title: Therapeutic potential and challenges of natural killer cells in treatment of solid tumors
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2015.00202
– volume: 5
  start-page: 112
  year: 1975
  ident: B2
  article-title: “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype
  publication-title: Eur J Immunol
  doi: 10.1002/eji.1830050209
– volume: 195
  start-page: 2580
  year: 2015
  ident: B28
  article-title: Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1500262
– volume: 17
  start-page: 678
  year: 2011
  ident: B39
  article-title: Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-2173
– reference: 24326534 - Blood. 2014 Jan 30;123(5):678-86
– reference: 24504444 - Ann Oncol. 2014 Mar;25(3):747-53
– reference: 21248148 - J Leukoc Biol. 2011 Apr;89(4):625-38
– reference: 24646734 - J Immunol. 2014 Apr 15;192(8):3805-15
– reference: 21708957 - Cancer Res. 2011 Aug 15;71(16):5412-22
– reference: 19531227 - BMC Cancer. 2009 Jun 16;9:186
– reference: 21552268 - Nat Med. 2011 Jun;17(6):700-7
– reference: 23563087 - Cell Mol Immunol. 2013 May;10(3):202-12
– reference: 27777574 - Front Immunol. 2016 Oct 10;7:413
– reference: 22934253 - Oncoimmunology. 2012 Aug 1;1(5):609-617
– reference: 24204708 - PLoS One. 2013 Oct 18;8(10):e76928
– reference: 24225017 - Cancer Res. 2014 Jan 1;74(1):81-92
– reference: 27406745 - Nat Commun. 2016 Jul 13;7:12258
– reference: 19552894 - J Immunol Methods. 2009 Aug 31;348(1-2):9-17
– reference: 15536148 - Blood. 2005 Mar 15;105(6):2594-600
– reference: 14523385 - Nat Rev Immunol. 2003 Oct;3(10):781-90
– reference: 21383766 - Immunol Cell Biol. 2012 Jan;90(1):109-15
– reference: 21841316 - J Clin Invest. 2011 Sep;121(9):3609-22
– reference: 9486650 - Nature. 1998 Feb 19;391(6669):795-9
– reference: 10649250 - Cancer. 2000 Feb 1;88(3):577-83
– reference: 10770793 - J Exp Med. 2000 Apr 17;191(8):1259-62
– reference: 20581313 - Blood. 2010 Oct 7;116(14):2411-9
– reference: 19561305 - Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84
– reference: 21325295 - Clin Cancer Res. 2011 Feb 15;17(4):678-89
– reference: 18424763 - J Immunol. 2008 May 1;180(9):6392-401
– reference: 12370276 - J Clin Invest. 2002 Oct;110(7):983-92
– reference: 16940427 - Blood. 2007 Jan 1;109(1):323-30
– reference: 11244035 - Annu Rev Immunol. 2001;19:197-223
– reference: 11385371 - J Thorac Cardiovasc Surg. 2001 Jun;121(6):1058-63
– reference: 14764669 - J Immunol. 2004 Feb 15;172(4):2048-58
– reference: 20302958 - Biol Blood Marrow Transplant. 2010 Sep;16(9):1257-64
– reference: 21660134 - J Biomed Biotechnol. 2011;2011:379123
– reference: 21219185 - Annu Rev Immunol. 2011;29:235-71
– reference: 19553639 - Blood. 2009 Sep 24;114(13):2667-77
– reference: 28197361 - Oncoimmunology. 2016 Apr 25;6(1):e1137418
– reference: 23002117 - Blood. 2012 Nov 22;120(22):4317-23
– reference: 23454771 - J Clin Invest. 2013 Mar;123(3):1371-81
– reference: 1080480 - Int J Cancer. 1975 Aug 15;16(2):230-9
– reference: 1234049 - Eur J Immunol. 1975 Feb;5(2):112-7
– reference: 24715892 - Front Immunol. 2014 Mar 24;5:122
– reference: 17673900 - Leukemia. 2007 Oct;21(10):2145-52
– reference: 3815344 - Cancer Res. 1987 Mar 1;47(5):1411-2
– reference: 16397273 - Cancer Res. 2006 Jan 1;66(1):563-70
– reference: 15032581 - Annu Rev Immunol. 2004;22:329-60
– reference: 26944201 - Immunity. 2016 Mar 15;44(3):609-21
– reference: 23033266 - Blood. 2012 Nov 22;120(22):4324-33
– reference: 20938360 - Melanoma Res. 2010 Dec;20(6):459-67
– reference: 28197362 - Oncoimmunology. 2016 May 13;6(1):e1163456
– reference: 14685277 - EMBO J. 2004 Jan 28;23(2):255-9
– reference: 16648500 - J Clin Oncol. 2006 May 1;24(13):1997-2005
– reference: 11117911 - Lancet. 2000 Nov 25;356(9244):1795-9
– reference: 17575122 - Cancer Res. 2007 Jun 15;67(12):5594-9
– reference: 19109559 - Blood. 2009 Apr 16;113(16):3735-43
– reference: 26402368 - Hum Vaccin Immunother. 2016 Mar 3;12(3):607-11
– reference: 18394936 - Immunity. 2008 Apr;28(4):571-80
– reference: 22031859 - Blood. 2011 Dec 8;118(24):6387-91
– reference: 23348417 - Nat Rev Immunol. 2013 Feb;13(2):145-9
– reference: 22446501 - Leukemia. 2012 Sep;26(9):2019-26
– reference: 20551059 - Cancer Res. 2010 Jul 1;70(13):5213-9
– reference: 20828749 - J Surg Res. 2011 Dec;171(2):637-49
– reference: 24488563 - Haematologica. 2014 May;99(5):836-47
– reference: 21169256 - Clin Cancer Res. 2010 Dec 15;16(24):6040-8
– reference: 23592754 - Cancer Res. 2013 Jun 15;73(12):3499-510
– reference: 23785047 - Clin Cancer Res. 2013 Aug 1;19(15):4079-91
– reference: 25351955 - Cancer Res. 2014 Dec 15;74(24):7298-308
– reference: 8822949 - Blood. 1996 Sep 15;88(6):2279-87
– reference: 18650461 - Blood. 2008 Aug 1;112(3):461-9
– reference: 25972872 - Front Immunol. 2015 Apr 29;6:202
– reference: 11750709 - Lung Cancer. 2002 Jan;35(1):23-8
– reference: 20404273 - J Immunol. 2010 May 15;184(10):5637-44
– reference: 17295095 - Clin Exp Metastasis. 2007;24(1):1-11
– reference: 25041786 - Eur J Immunol. 2014 Oct;44(10):3068-80
– reference: 24295643 - FEBS Lett. 2014 Jan 21;588(2):288-97
– reference: 26753005 - Ther Adv Med Oncol. 2016 Jan;8(1):48-56
– reference: 21193697 - Blood. 2011 Feb 24;117(8):2423-32
– reference: 21676435 - Hum Pathol. 2011 Dec;42(12):1960-4
– reference: 27563819 - Oncotarget. 2016 Sep 20;7(38):60858-60871
– reference: 11896281 - Science. 2002 Mar 15;295(5562):2097-100
– reference: 9191519 - Cancer. 1997 Jun 15;79(12):2320-8
– reference: 19483647 - J Immunother. 2009 Jul-Aug;32(6):622-31
– reference: 26246143 - J Immunol. 2015 Sep 15;195(6):2580-90
– reference: 11986221 - Blood. 2002 May 15;99(10):3661-7
– reference: 22754766 - Oncoimmunology. 2012 Jul 1;1(4):477-486
– reference: 28123867 - Oncoimmunology. 2016 Mar 10;5(12 ):e1154251
– reference: 24731302 - J Hematol Oncol. 2014 Apr 14;7:33
– reference: 2471777 - J Exp Med. 1989 Jun 1;169(6):2233-8
SSID ssj0000493335
Score 2.2077641
Snippet Natural killer (NK) cells are potent antitumor effectors, involved in hematological malignancies and solid tumor immunosurveillance. They infiltrate various...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 683
SubjectTerms AMLMDS
BRAF inhibitor
immune checkpoint inhibitors
Immunology
melanoma
natural killer ligands
tumour immunosurveillance
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxsxEBYlEOil9Jm6j6BCLz0sllfP7a0NCaYFU4oNzklIuxJxsdchax96y9_I3-sv6YzkGDuE9NLLHrQSK76ZRd-gmW8I-aj0QBovWBGdhABFRFF4VQ4KWTvHuQyoKILZFiM1nIhvUzndafWFOWFZHjgD13fAQWoDsQ5EKiJI74VBCbgqclY6lyu3WMV2gqlfmfdy-FS-l4QorOrH2WKxxlQulCxUhu-dQ0mu_z6OeTdVcufsOXtKnmxII_2SN_uMPArtc3KY20j-fkHOf2Rx1D_XNx0duaSkQb-nIj96Eubzjs5aCkSPnl45uox0nLK_Q0PHqfgKYuXP9OdyHigQWDpeL-CZV3cvyeTsdHwyLDYtE4paqHJVNKYRrBG6GQRvlBReOy-V0BGZtOTKK1_FeqAjsC4WdePKhsnaKA1Ex2uu-Cty0C7b8JpQp2AEbwHxBBdc-1qw2DATa4-i6qxH-rcA2nqjJ45tLeYW4gqE3CbILUJuE-Q98mm74jJraTww9yvaZDsPVbDTAPiG3fiG_Zdv9MiHW4ta-GvwKsS1YbnuLKraGYkdCXvkKFt4-yms1a2qElbrPdvv7WX_TTu7SMrcCFal5Jv_sfm35DHCUaQ-Se_IwepqHd4DAVr54-TrfwERYQDn
  priority: 102
  providerName: Directory of Open Access Journals
Title Patient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers
URI https://www.ncbi.nlm.nih.gov/pubmed/28659921
https://www.proquest.com/docview/1914850018
https://pubmed.ncbi.nlm.nih.gov/PMC5466965
https://doaj.org/article/a019c89782114e5bb4803289f302aa01
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3di9QwEA96Ivgift_q3RFBEB_qtc1nD-TQ485D8RDZxX0LSZvoSrfV7S54_70zaW91ZRFf8pCPpp0kzG-amd8Q8kyqTGjH0yRYAQYKDzxxMs8SUVrLmPDIKILeFhfyfMLfTcX0d3j0IMBuq2mH-aQmi_rlzx-Xx3DgX6HFCfr2MMzm8xV6aSEbodTsOrkBekmiKfZhAPvfeizMWMy4mUnJE9jJvL-33PqQDT0V6fy3YdC_XSn_0E1nd8jtAVTS1_0uuEuu-eYeudmnmby8Tz5_7MlTn3f0wkaeDfo-hgDSE1_XHZ01FGAgPV1Y2gY6jr7hvqLjGJoFlvQR_dTWngK8pePVHMp-dPeATM5OxyfnyZBQISm5zJdJpSueVlxVmXdaCu6UdUJyFRBnCyaddEUoMxUAk6VBVTavUlFqqQAGOcUke0h2mrbxu4RaCTV4R4j6nTPlSp6GKtWhdEi5no7I4ZX4TDmwjWPSi9qA1YECN1HgBgVuosBH5MV6xPeeaeMffd_giqz7IUd2rGgXX8xw5IwF9FpqsJLBxuVeOMc1kgcWgaW5hcYReXq1ngbOFF6U2Ma3q84g550WmK9wRB7167ueCiN5iyKH0Wpj5TfeZbOlmX2NvN0orEKKx_8x7xNyC782iUmS9sjOcrHy-4B-lu4g_jWA8u00O4gb_Bdw1gGM
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Patient%27s+Natural+Killer+Cells+in+the+Era+of+Targeted+Therapies%3A+Role+for+Tumor+Killers&rft.jtitle=Frontiers+in+immunology&rft.au=Messaoudene%2C+Meriem&rft.au=Frazao%2C+Alexandra&rft.au=Gavlovsky%2C+Pierre+Jean&rft.au=Toubert%2C+Antoine&rft.date=2017-06-12&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=8&rft.spage=683&rft_id=info:doi/10.3389%2Ffimmu.2017.00683&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon